Top Markets
#1 Islamic Coin Islamic Coin +154.29%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +30.82%
#4 RedStone RedStone +16.61%
#5 Bio Protocol Bio Protocol +16.57%
#6 edgeX edgeX +15.25%
#7 rsERG rsERG +12.23%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.05%
#9 SkyAI SkyAI +11.71%
#10 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +11.42%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
AIxCrypto Holdings, Inc. AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc.

AIXC
Rank in Stocks #27458
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company... AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Share Price
$1.62
Last synced: 2026-08-19
Market Cap
$32.77M
Change (1 day)
22.67%
Change (1 year)
-13.87%
Country
US
Trade AIxCrypto Holdings, Inc. (AIXC)

Category

Healthcare
Revenue for AIxCrypto Holdings, Inc. (AIXC)
Revenue in Aug 2026 TTM: 0
According to AIxCrypto Holdings, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AIxCrypto Holdings, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT